GLP‑1 pills are here - Wegovy pill and Foundayo explained

Introduction

For years, the most effective GLP‑1 medications for weight loss were available only as weekly injections. That changed in 2025 and 2026 with the FDA approval of two oral options: the Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026). For people who dislike needles, travel frequently, or simply prefer a daily pill, these medications open a new path to treatment. This article compares both options so you can have an informed conversation with your provider.

How the two pills differ

Although both medications target the GLP‑1 receptor to reduce appetite and slow digestion, their underlying chemistry is meaningfully different:

• Wegovy pill contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic. Semaglutide is a large peptide molecule that is poorly absorbed in the stomach, so the pill includes an absorption enhancer called SNAC. You must take it first thing in the morning on an empty stomach with no more than four ounces of water, then wait at least 30 minutes before eating, drinking, or taking other oral medications.
• Foundayo contains orforglipron, a completely different small-molecule GLP‑1 agonist developed by Eli Lilly. Because orforglipron is not a peptide, it passes through the digestive system more easily and can be taken at any time of day, with or without food, and without water restrictions.

This difference in daily routine is one of the most practical distinctions between the two medications.

Effectiveness and clinical trial results

Both pills produce meaningful weight loss, though the results are not identical:

• Wegovy pill: Clinical trials showed approximately 14 to 16.6 percent average weight loss at the maintenance dose of 25 mg daily. The titration schedule escalates over several weeks to reach this dose.
• Foundayo: Clinical trials showed approximately 11 to 12.4 percent average weight loss. The titration starts at 0.8 mg and increases over several months through up to six dose levels, with a maximum maintenance dose of 17.2 mg.
• Injectable comparison: For context, injectable Wegovy (semaglutide 2.4 mg) achieves roughly 15 to 17 percent weight loss, and injectable Zepbound (tirzepatide 15 mg) achieves roughly 20 to 22.5 percent.

No head-to-head trial between the Wegovy pill and Foundayo has been published, so these comparisons are indirect and should be interpreted with caution.

Side effects to expect

Both medications share the common gastrointestinal side effects typical of the GLP‑1 class:

• Nausea: The most frequently reported side effect for both, typically worst during dose escalation and improving over time.
• Diarrhea, vomiting, and constipation: Common across both medications during the titration period.
• Foundayo-specific: Orforglipron may have slightly higher rates of GI side effects and is more likely to cause a small increase in heart rate (approximately four beats per minute) compared to oral semaglutide.

Both medications carry boxed warnings for thyroid C-cell tumors and are approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition.

Choosing between the two

The best choice depends on your lifestyle and medical profile:

• If dosing convenience matters most: Foundayo has no fasting requirement and can be taken at any time of day, making it easier for people with busy or irregular schedules.
• If maximum weight loss is the priority: The Wegovy pill shows higher average weight loss in trials, though the strict morning routine is a real commitment.
• If you are already on injectable semaglutide: Switching to the Wegovy pill keeps you on the same active ingredient, which may simplify the conversation with your provider and insurer.
• Cost and insurance: Coverage varies significantly. Check with your insurer, as both manufacturers offer savings programs for eligible patients.

Track your oral GLP‑1 with Shotsy

Shotsy supports daily oral GLP‑1 tracking with pill-specific features. Log your fasting time and water consumed with each dose, set daily reminders, and track weight, nutrition, and side effects the same way injectable users do. Both Wegovy Pill and Foundayo are built into the app with their own dosage options.

Conclusion

The arrival of effective oral GLP‑1 medications is a significant moment for weight management. Whether you choose the Wegovy pill or Foundayo, you now have options beyond injections. Talk to your provider about which fits your health profile and daily routine, and remember that the best medication is the one you can take consistently.